Phosphatidate phosphatase LPIN2 (LPIN2)

Phosphatidate phosphatase LPIN2 (Lipin-2, LPIN2) is an Mg²⁺-dependent enzyme that catalyzes the conversion of phosphatidic acid to diacylglycerol in the glycerolipid biosynthesis pathway, playing a key role in triglyceride and membrane phospholipid synthesis[3][5][6]. It is widely expressed in liver, brain, and kidney[5][6], and helps regulate inflammation by controlling NLRP3 inflammasome activity[1][4]. LPIN2 is critical in bone remodeling and blood cell production, and mutations cause Majeed syndrome, a rare autoinflammatory disorder with recurrent bone inflammation, anemia, and neutrophilic dermatosis[1][3][4]. It also contributes to transcriptional regulation via interaction with nuclear receptors and coactivators in metabolic tissues[5]. There are no approved drugs directly targeting LPIN2, but its activity represents a potential therapeutic node for metabolic, inflammatory, and bone diseases[3][4][5][6].

Other names

Lipin-2LPIN2KIAA0249Phosphatidate phosphatase LPIN2CRMO1MJDS

Hypothetically, modulation of LPIN2 activity would alter lipid metabolic flux, reduce phosphatidic acid levels, affect chylomicron production, and regulate inflammatory response by controlling NLRP3 inflammasome activity